Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Invesco DB Agriculture Fund (DBA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Invesco DB Agriculture Fund — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Invesco DB Agriculture Fund trades at $27.59. Which is the better fit depends on your goals.
| ACAD | DBA | |
|---|---|---|
Market Cap | $4.49B | — |
Sector | Health | — |
52-Week High | $28.06 | $28.73 |
52-Week Low | $20.06 | $25.44 |
Enterprise Value | $3.69B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
DBA (Invesco DB Agriculture Fund) trades at $27.54, up 2.99% with strong bullish technical signals from moving averages. The fund tracks agricultural commodities including corn, soybeans, and livestock futures. Recent news highlights supply disruptions in Brazil's coffee harvest and China's $17 billion crop purchase commitment through 2028, creating favorable conditions for agricultural ETFs.
The agricultural commodity rally presents upside potential, though overbought RSI readings suggest near-term consolidation. Key risks include weather volatility affecting crop yields and geopolitical impacts on global trade flows. The fund's diversified exposure offers hedging benefits against inflation but remains sensitive to commodity price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →
